SEC Tracker
Get the app

Moleculin Biotech MBRX

Moleculin Biotech announces Annamycin data acceptance for ASH meeting

Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Routine
  1. An abstract on Annamycin's Phase 2/3 trial data accepted for ASH 2026 meeting
  2. 43% and 36% complete remission rates in Annamycin arms vs 12% in placebo
  3. No cardiotoxicity observed in first 45 patients
  4. Second interim analysis expected in early 2027

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Moleculin Biotech files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. GT Biopharma GTBP public float $9M, Jun 30, 2025
  2. TherapeuticsMD TXMD public float $9M, Jun 30, 2025
  3. Oncotelic Therapeutics OTLC public float $9M, Jun 30, 2025
  4. Biovie BIVI public float $8M, Dec 31, 2025
  5. Artelo Biosciences ARTL public float $9M, Jun 30, 2025